Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
LYEL Stock Chart & Stats
$24.34
-$0.01(-1.66%)
At close: 4:00 PM EST
$24.34
-$0.01(-1.66%)
Day’s Range― - ―
52-Week Range$7.65 - $45.00
Previous CloseN/A
Volume124.06K
Average Volume (3M)94.38K
Market Cap
$517.08M
Enterprise Value$469.65M
Total Cash (Recent Filing)$319.62M
Total Debt (Recent Filing)$44.28M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Mar 04, 2026EPS Estimate
-2.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding21,243,954
10 Day Avg. Volume79,550
30 Day Avg. Volume94,378
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.44
Price to Sales (P/S)2743.40
P/FCF Ratio-1.03
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue11.45K
Enterprise Value/Gross Profit11.45K
Enterprise Value/Ebitda-2.47
Forecast
1Y Price Target
$28.50Price Target Upside17.09% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyHigh-dose LYL273 produced pronounced tumor responses and meaningful disease control in a small cohort of pretreated colorectal cancer patients, indicating potential activity in treatment-resistant tumors.
Competitive PositioningMechanistic differentiation and emerging durability signals distinguish Lyell's approach from peers, strengthening the company’s leadership narrative and reducing near-term competitive threats.
KOL EndorsementKOL feedback characterized diarrhea as transient and reversible and judged the benefit–risk favorable, supporting clinical confidence in LYL273 for colorectal cancer.
Bears Say
Commercial UncertaintyUncertainty around sustained durability and whether toxicity can be managed at scale undermines conviction in long-term revenue potential and valuation assumptions.
Data RobustnessSmall patient numbers and immature durability data limit the ability to project long-term benefits or to build reliable commercial forecasts.
Safety RiskA reported colitis-related fatality and the reliance on protocolized diarrhea prophylaxis highlight unresolved safety challenges that could hinder broader adoption.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $7.65 and its highest was $45.00 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Lyell Immunopharma’s market cap is $517.08M.
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Mar 04, 2026 which is in 18 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Nov 12, 2025. The company reported -$2.13 earnings per share for the quarter, beating the consensus estimate of -$2.642 by $0.512.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -2.37.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 21,243,954 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$2.13 in its last earnings report, beating expectations of -$2.642. Following the earnings report the stock price went down -1.248%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Currently, no hedge funds are holding shares in LYEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lyell Immunopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$28.50 (17.09% Upside)
$28.50 (17.09% Upside)
Blogger Sentiment
Bullish
LYEL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 98.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $264.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 13.9%
Last 30 Days ▼ 13.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.38%
12-Months-Change
Fundamentals
Return on Equity
-75.75%
Trailing 12-Months
Asset Growth
-34.12%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL Stock 12 Month Forecast
Average Price Target
$28.50
▲(17.09% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Replimune Group
―
―
Ownership Overview
30.70% Insiders
7.49% Mutual Funds
0.09% Other Institutional Investors
57.09% Public Companies and
Individual Investors